Biotheus Inc.
2025
$800M
Why
BioNTech acquired Biotheus to secure full global rights to BNT327 (PM8002), a novel bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization. The acquisition also added an in-house antibody generation platform, bispecific ADC capabilities, and a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
Impact
The acquisition transformed BioNTech's oncology pipeline by adding a late-stage bispecific antibody with registrational trial potential in three major cancer indications. It established a dual-hemisphere manufacturing footprint and provided access to the Chinese pharmaceutical market. The deal closed in February 2025 after signing in November 2024.
Outcome
BNT327 is now BioNTech's lead oncology asset, with over 750 patients treated across trials and registrational programs initiated in first-line SCLC, NSCLC, and TNBC. The first oncology launch is targeted for 2026 if regulatory approvals are achieved.